Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 5/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | PLA2G4A | P47712 | 4/20 | 0.42 |
| ▸ | ADH5 | P11766 | 4/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | USP14 | P54578 | 1/20 | 0.36 |
| ▸ | HAT1 | O14929 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22076963 | 0.91 | TBXAS1 (0.49) | TBXAS1PLA2G4AADH5CYP2C19SLC22A12 | |
| SCHEMBL22076995 | 0.89 | TBXAS1 (0.47) | TBXAS1PLA2G4AADH5CYP2C19PRMT5 | |
| SCHEMBL22078066 | 0.89 | USP14 (0.49) | TBXAS1PLA2G4ASLC22A12USP14HAT1 | |
| SCHEMBL22078067 | 0.89 | TBXAS1 (0.47) | TBXAS1PLA2G4A | |
| SCHEMBL22078076 | 0.85 | TBXAS1 (0.53) | TBXAS1PLA2G4AADH5CYP2C19SLC22A12 | |
| SCHEMBL25492040 | 0.83 | ENPP2 (0.41) | TBXAS1ENPP2MKNK1MKNK2CYP2C19 | |
| SCHEMBL20536447 | 0.80 | TBXAS1 (0.48) | TBXAS1ADH5CYP2C19PRMT5WDR77 | |
| SCHEMBL30772956 | 0.80 | TBXAS1 (0.48) | TBXAS1ADH5CYP2C19PRMT5WDR77 | |
| SCHEMBL22077233 | 0.80 | ADH5 (0.61) | TBXAS1PLA2G4AADH5CYP2C19SLC22A12 | |
| SCHEMBL25493548 | 0.80 | ADH5 (0.45) | TBXAS1PLA2G4AADH5CYP2C19SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655244-B2 | Carbazole compounds and methods of use thereof | GSNO THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20200181129-A1 | CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF | GSNO THERAPEUTICS, INC. | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655244-B2 | Carbazole compounds and methods of use thereof | GSR, CBR3, CBR1 | TBXAS1 1031/4885ENPP2 3281/4885MKNK1 4345/4885 |
| US-20200181129-A1 | CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF | GSR, CBR3, CBR1 | TBXAS1 1031/4885ENPP2 3281/4885MKNK1 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.